Author:
Singer Christian F.,Gschwantler-Kaulich Daphne,Fink-Retter Anneliese,Pfeiler Georg,Walter Ingrid,Hudelist Gernot,Helmy Samir,Spiess Anne-Catherine,Lamm Wolfgang,Kubista Ernst
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology,General Medicine
Reference26 articles.
1. Bilous M, Ades C, Armes J, Bishop J, Brown R, Cooke B, Cummings M, Farshid G, Field A, Morey A, McKenzie P, Raymond W, Robbins P, Tan L (2003) Predicting the HER2 status of breast cancer from basic histopathology data: an analysis of 1,500 breast cancers as part of the HER2000 international study. Breast 12(2):92–98. doi: 10.1016/S0960-9776(02)00273-4
2. Birner P, Oberhuber G, Stani J, Reithofer C, Samonigg H, Hausmaninger H, Kubista E, Kwasny W, Kandioler-Eckersberger D, Gnant M, Jakesz R (2001) Austrian breast and colorectal cancer study group. Evaluation of the United States food and drug administration-approved scoring and test system of HER-2 protein expression in breast cancer. Clin Cancer Res 7(6):1669–1675
3. Biswas DK, Cruz AP, Gansberger E, Pardee AB (2000) Epidermal growth factor-induced nuclear factor kappa B activation: a major pathway of cell-cycle progression in estrogen-receptor negative breast cancer cells. Proc Natl Acad Sci USA 97:8542–8547. doi: 10.1073/pnas.97.15.8542
4. Ciocca D, Fujimura F, Tandon A, Clark G, Mark C, Lee-Chen G, Pounds G, Vendely P, Owens M, Pandian M (1992) Correlation ofHER-2/neu amplificationwith expression and with other prognostic factors in 1,103 breast cancers. J Natl Cancer Inst 84:1279–1282. doi: 10.1093/jnci/84.16.1279
5. Early Breast Cancer Trialists’ Collaborative Group (1998) Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351(9114):1451–1467. doi: 10.1016/S0140-6736(97)11423-4